In present study, streptozodicine was administrated to rats for induction of diabetes and although this type of diabetes has no prolonged clinical features as that for human is a suitable model for the study of diabetic wound [
16]. Considering the mean number of mast cells, it seems that the type 2 of mast cells in all PTX treated groups was significantly increased in the day 7 after surgery. Although the mean number of type 3 of mast cells in DB+PTX group in comparing with control ones in the day 7 after surgery was lower, this decrease was not significant. However, considering the rate of decrease in type 3 of mast cells in the days 3 and 7 in DB+PTX group in comparison with DB+DW it seems that PTZ could delay the maturation process of type 2 to 3 of mast cells. The data showed that the type 3 of mast cells was reduced in NG+PTX group in comparison with control one and in other words, PTX caused a delay for maturation of the type 2 to 3 of mast cells. According these data, PTX could be considered as a modulator of maturation of type 2 to type 3 of mast cells. Many studies showed that reduction of the components of inflammation procedure such as degranulation of mast cells has positive effect on wound healing [
4,
17]. In diabetes mellitus, because of high level of serum glucose, decrease in the rate of replication of the cells exactly in fibroblasts induces that causes deficient in collagen synthesis during wound healing [
9,
18-
22]. In present study it also showed that delay in wound healing process in diabetic group in comparison with control group was occurred in parallel with increasing in the number of type 3 of mast cells. But considering timing, it seems maturation of type 2 to 3 of mast cells in all PTX treated groups occurred and this data showed that maturation of mast cells in DB+PTX has a similar pattern as that for normal group. In other words, if the timing of the experiment were longer and the diabetic rats administrated longer with PTX, process of maturation of type 2 to 3 of mast cells was shown more similarity between diabetic and normoglycemic groups.
The study showed although the number of total mast cells in PTX groups was lower this decrease was not statistically significant. Recent studies showed that mast cells are involved for creating scar tissue during wound healing process [
19]. Thus, reduction of the number of mast cells that was similar to normal rats may consider for clinical application of PTX for omitting scar tissue of wounds and this effect of PTX could be resulted by decreasing in the number of fibroblasts [
19-
22]. Some studies showed that IL-1α, IL-9, prostaglandin E2, monocyte chemotactic protein-1 are factors that could increase accumulation of mast cells by a mechanism related to fibroblasts [
23] and because PTX has blocking effect on fibroblasts, this efficacy could indirectly suppress occurrence of scar. On the other hand, recent studies are shown that PTX are able to decrease tissue damage regarding to inflammatory factors of neutrophils such as IL-1, TNF-α and because IL-1 is a inducer factor for progression of mast cells, PTX by blocking IL-1 suppress the maturation of mast cells [
24].
It also been shown that during normal wound healing, there are a few changes in the amount of monocyte chemotactic protein-1 (MCP-1) along with degranulation of mast cells [
10,
20]. Recent data showed that PTX was decreased the expression of MCP-1 in a dose dependent manner [
25,
26] that finally caused the decreasing in the progression of inflammation, increase in the velocity of healing process and blocking in scar formation. The study adds that PTX does these effects by increasing in the number of type 2 of mast cells and also recucting in the maturation process of type 2 to 3 of mast cells.
Further investigations need for other probable mechanisms that could affect delay of maturation of type 2 to 3 of mast cells derived by PTX. Here it is suggested that by conducting a similar study, different doses of PTX with longer follow up could evaluate accurately the effect of PTX on maturation of mast cells.